% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Chen:294079,
      author       = {B. Chen and Y. He and L. Bai and S. Pan and Y. Wang and M.
                      Mu and R. Fan and B. Han and P. Huber$^*$ and B. Zou and G.
                      Guo},
      title        = {{R}adiation-activated {PD}-{L}1 aptamer-functionalized
                      nanoradiosensitizer to potentiate antitumor immunity in
                      combined radioimmunotherapy and photothermal therapy.},
      journal      = {Journal of materials chemistry / B},
      volume       = {12},
      number       = {47},
      issn         = {2050-750X},
      address      = {London ˜[u.a.]œ},
      publisher    = {RSC},
      reportid     = {DKFZ-2024-02100},
      pages        = {12220-12231},
      year         = {2024},
      note         = {2024 Dec 4;12(47):12220-12231},
      abstract     = {Reactive oxygen species (ROS)-mediated immunogenic cell
                      death (ICD) is crucial in radioimmunotherapy by boosting
                      innate antitumor immunity. However, the hypoxic tumor
                      microenvironment (TME) often impedes ROS production,
                      limiting the efficacy of radiotherapy. To tackle this
                      challenge, a combination therapy involving radiotherapy and
                      immune checkpoint blockade (ICB) with anti-programmed
                      death-ligand 1 (PD-L1) has been explored to enhance
                      antitumor effects and reprogram the immunosuppressive TME.
                      Here, we introduce a novel PD-L1 aptamer-functionalized
                      nanoradiosensitizer designed to augment radiotherapy by
                      increasing X-ray deposition specifically at the tumor site.
                      This innovative X-ray-activated nanoradiosensitizer,
                      comprising gold-MnO2 nanoflowers, efficiently enhances ROS
                      generation under single low-dose radiation and repolarizes
                      M2-like macrophages, thereby boosting antitumor immunity.
                      Additionally, the ICB inhibitor BMS-202 synergizes with the
                      PD-L1 aptamer-assisted nanoradiosensitizer to block the
                      PD-L1 receptor, promoting T cell activation. Furthermore,
                      this nanoradiosensitizer exhibits exceptional photothermal
                      conversion efficiency, amplifying the ICD effect. The
                      PD-L1-targeted nanoradiosensitizer effectively inhibits
                      primary tumor growth and eliminates distant tumors,
                      underscoring the potential of this strategy in optimizing
                      both radioimmunotherapy and photothermal therapy.},
      cin          = {E055},
      ddc          = {610},
      cid          = {I:(DE-He78)E055-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39420720},
      doi          = {10.1039/D4TB01831A},
      url          = {https://inrepo02.dkfz.de/record/294079},
}